Acalabrutinib, the second-generation BTK inhibitor with greater selectivity, has been approved by the FDA for use in previously treated mantle cell lymphoma and newly diagnosed CLL [179, 180]. The gene discussed is BTK; the disease is mantle cell lymphoma.